Malignant tumor
Conditions
Interventions
Group B:Standard two combination antiemetic regimen
Sponsors
Ordos Central Hospital, Inner Mongolia
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients older than 18 years with a Karnofsky performance scale >= 70 scheduled to receive carboplatin-based chemotherapy (25 mg/m2/d) were enrolled in the study; 2. All patients had histologically confirmed solid tumors; 3. Before chemotherapy, liver and kidney function, blood routine, electrocardiogram are normal.Blood tests must meet the requirements of white blood cells > 3.5 * 10^9, neutrophils > 1.5 *10^9, platelets > 85 *10^9, alkaline phosphatase less than 2.5 times of normal value, glutamic pyruvic transaminase 2.5 times of normal value, bilirubin 1.5 times of normal value, and creatinine 1.5 times of normal value. 4. CT and (MRI) evaluated the tumor site without chemotherapy contraindications; 5. Had no symptoms of nausea and vomiting one week before entering the group, and had not been treated with aprepitant or olanzapine; 6. Obtain the patient's informed consent and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. Primary exclusion criteria were: patients who were unable to take oral drugs and had a long history of hormone use; 2. Those who received radiotherapy at the same time and those who had vomiting 24 hours before chemotherapy; 3. Symptomatic primary or metastatic central nervous system metastasis and and patients who have received brain radiotherapy; 4. Pregnant or breast-feeding; 5. Concurrent quinolone antibiotic therapy; 6. Partial/complete bowel obstruction; 7. Known hypersensitivity to 5-HT3 receptor; 8. Aprepitant,and olanzapine; 9. Treatment with illegal drugs or evidence of alcohol abuse; 10. Patients with gastrointestinal tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall phase complete response;FLIE scale;Malignant score;Side effects;the proportion of patients with total protection; | — |
Secondary
| Measure | Time frame |
|---|---|
| the proportion of patients with total protection;the proportion of patients with complete control; | — |
Countries
China
Contacts
Public ContactLi Quanfu
Ordos Central Hospital, Inner Mongolia; Ordos clinical Medical College, Baotou Medical College
Outcome results
None listed